Gilead Sciences, Inc. is a research-based biopharmaceutical company headquartered in Foster City, California that focuses on the discovery, development, and commercialization of innovative medicines.
Facente Consulting is providing training and technical assistance to grant recipients of the Gilead Oncology Corporate Giving Program to support them in evaluating the impact of programs on improving outcomes and health equity among people affected by cancer.
Facente Consulting supported Gilead Sciences with statistical analysis relating to HIV incidence rates, assisting with the study design, analysis plan, and interpretation of study data for the PURPOSE trials--ultimately leading to the groundbreaking FDA approval of the twice-yearly PrEP medication Lenacapavir.